Insider Buying: Zoetis (NYSE:ZTS) Director Buys $233,280.00 in Stock

Zoetis Inc. (NYSE:ZTS) Director Michael Mccallister bought 3,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Zoetis Trading Up 1.7%

ZTS opened at $75.57 on Friday. Zoetis Inc. has a 1-year low of $73.98 and a 1-year high of $172.23. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The company has a market cap of $31.68 billion, a P/E ratio of 12.53, a price-to-earnings-growth ratio of 1.21 and a beta of 0.87. The company has a fifty day moving average price of $113.32 and a two-hundred day moving average price of $121.27.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period last year, the firm posted $1.48 earnings per share. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts predict that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Analyst Ratings Changes

ZTS has been the subject of several research analyst reports. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. BTIG Research reaffirmed a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Citigroup initiated coverage on shares of Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price target for the company. Finally, Bank of America lifted their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Zoetis has an average rating of “Hold” and a consensus target price of $141.25.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis during the fourth quarter valued at about $25,000. Prosperity Bancshares Inc acquired a new position in shares of Zoetis during the fourth quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis during the third quarter valued at about $31,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Zoetis during the first quarter valued at about $28,000. Finally, Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the fourth quarter valued at about $30,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.